In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emerging Markets Will Lead World Healthcare Market Growth, With China’s Healthcare Reform Shuffling Drug Distribution: Shanghai Bio-Forum

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Developing countries will be the first and fastest to recover from the global economic downturn, and emerging healthcare markets in those countries will lead growth rates in the future, Zhu Baoquan, former president of the Shanghai Institute of Pharmaceutical Industry, said June 1 during the Bio-Forum conference in Shanghai

You may also be interested in...



China’s Essential Drug System Expected To Consolidate Generic Industry, Promote Innovative R&D

SHANGHAI - China's essential drug system will hasten the consolidation of the generic industry while a measure for drug pricing will encourage innovation, according to a Frost & Sullivan report on the impact of China's healthcare reform, released May 18

Sanofi-Aventis Sees Diversifying In China As Key To Success; Expands Capacity For Diabetes Treatment Lantus

SHANGHAI - Sanofi-Aventis announced a series of expansion plans in China aimed at diversifying its portfolio, the CEO said April 21 during his first trip to China

China Issues Three-year Healthcare Reform Plan To Invest RMB 850 Billion

SHANGHAI - China issued its long-awaited three-year plan for its healthcare reform, and unveiled how the country will allocate RMB 850 billion ($124 billion) in the next three years

Related Content

UsernamePublicRestriction

Register

SC072070

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel